Literature DB >> 9038563

Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis.

F Seow-Choen1, V Vijayan, V Keng.   

Abstract

Eighteen patients with familial adenomatous polyposis (FAP) who had previously undergone colectomy but had upper gastrointestinal polyps were studied in a double-blind randomized crossover trial comparing sulindac with calcium and calciferol. Sulindac produced a reduction in the crypt proliferation index in the gastric epithelium of patients but did not significantly affect duodenal mucosa. Calcium with calciferol did not have any effects on crypt proliferation index in patients with FAP.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9038563     DOI： 10.1002/bjs.1800831232

Source DB:  PubMed          Journal:  Br J Surg        ISSN： 0007-1323            Impact factor:   6.939


  12 in total

Review 1.  Chemoprevention in familial adenomatous polyposis.

Authors:  Brian Kim; Francis M Giardiello
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 2.  Prevention and management of duodenal polyps in familial adenomatous polyposis.

Authors:  L A A Brosens; J J Keller; G J A Offerhaus; M Goggins; F M Giardiello
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  Pancreaticoduodenectomy for advanced duodenal and ampullary adenomatosis in familial adenomatous polyposis.

Authors:  James R A Skipworth; Clare Morkane; Dimitri Aristotle Raptis; Soumil Vyas; Steven W Olde Damink; Charles J Imber; Stephen P Pereira; Massimo Malago; Nicholas West; Robin K S Phillips; Sue K Clark; Arjun Shankar
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

Review 4.  Surveillance and management of upper gastrointestinal disease in Familial Adenomatous Polyposis.

Authors:  Michelle C Gallagher; Robin K S Phillips; Steffen Bulow
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 5.  Chemoprevention of familial adenomatous polyposis.

Authors:  Patrick M Lynch
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

6.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

Authors:  R K S Phillips; M H Wallace; P M Lynch; E Hawk; G B Gordon; B P Saunders; N Wakabayashi; Y Shen; S Zimmerman; L Godio; M Rodrigues-Bigas; L-K Su; J Sherman; G Kelloff; B Levin; G Steinbach
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

7.  Functional outcome after restorative proctocolectomy in pigs: comparing a novel transverse ileal pouch to the J-pouch and straight ileoanal anastomosis.

Authors:  F H Schmitz-Winnenthal; M Kadmon; E Schwab; L V Galindo; K Bläuer; A Niethammer; U Hinz; F Thomas; B M Schmied; R Nobiling; J Weitz; M W Büchler; K Z'graggen
Journal:  J Gastrointest Surg       Date:  2008-09-13       Impact factor: 3.452

8.  Surveillance and Treatment of Periampullary and Duodenal Adenomas in Familial Adenomatous Polyposis.

Authors:  J. Chad Johnson; James A. DiSario; William M. Grady
Journal:  Curr Treat Options Gastroenterol       Date:  2004-04

9.  Duodenal adenomatosis in familial adenomatous polyposis.

Authors:  S Bülow; J Björk; I J Christensen; O Fausa; H Järvinen; F Moesgaard; H F A Vasen
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 10.  Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.

Authors:  Patrycja Nowak-Sliwinska; Leonardo Scapozza; Ariel Ruiz i Altaba
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.